Results · Apr-Jun 2026
Samrat Pharmachem Q1 FY27 results
Sales grew 5% to ₹79.8 crore from ₹75.7 crore in Apr-Jun 2025.
Operating profit grew 623% to ₹0.9 crore, an operating margin of 1.1% (up 1.0 points from a year ago).
Net profit turned positive: ₹0.88 crore against a loss of ₹0.23 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales +11%, net profit turns positive.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 79.8 | 75.7 | +5% |
| Operating profit (EBITDA) | 0.9 | 0.1 | +623% |
| Operating margin | 1.1% | 0.2% | +1.0 pts |
| Net profit | 0.9 | -0.2 | turns positive |
Standalone figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
From the company's results filed on BSE (Standalone). Business numbers only. Education & analysis, not investment advice or a recommendation.